[1. E. Sousa, P. Serruys and M. Costa, New frontiers in cardiology: drug-eluting stents: Part I, Circulation 107 (2003) 2274-2279; DOI: 10.1161/01.CIR.0000069330.41022.90.10.1161/01.CIR.0000069330.41022.90]Search in Google Scholar
[2. E. Edelman and C. Rogers, Pathobiologic responses to stenting, Am. J. Cardiol. 81 (1998) 4E-6E; DOI: 10.1016/S0002-9149(98)00189-1.10.1016/S0002-9149(98)00189-1]Search in Google Scholar
[3. P. Serruys, B. Strauss and H. Van Beusekom, Stenting of coronary arteries: has a modern Pandora’s Box been opened? J. Am. Coll Cardiol. 17 (1991) 143B-154B; DOI: 10.1016/0735-1097(91)90951-5.10.1016/0735-1097(91)90951-5]Search in Google Scholar
[4. M. Costa, D. Foley and P. Serruys, Restenosis: the Problem and How to Deal With It, in Practical Interventional Cardiology (Eds. E. Grech and D. Ramsdale), 2nd ed., Martin Dumitz, London 2002, pp. 279-294.]Search in Google Scholar
[5. D. Whelan, H. Van Beusekom and W. Van der Giessen, Mechanisms of drug loading and release kinetics, Semin. Interv. Cardiol. 3 (1998) 127-131.]Search in Google Scholar
[6. W. Van der Giessen, A. Lincoff and R. Schwartz, Marked inflammatory sequelae to implantation of biodegradable and non-biodegradable polymers in porcine coronary arteries, Circulation 94 (1996) 1690-1697; DOI: 10.1161/01.CIR.94.7.1690.10.1161/01.CIR.94.7.1690]Search in Google Scholar
[7. D. Drachman, E. Edelman and P. Seifert, Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months, J. Am. Coll. Cardiol. 36 (2000) 2325-2332; DOI: 10.1016/S0735-1097(00)01020-2.10.1016/S0735-1097(00)01020-2]Search in Google Scholar
[8. B. Ratner, The blood compatibility catastrophe, J. Biomed. Mater. Res. 27 (1993) 283-287; DOI: 10.5897/AJPP11.107.10.5897/AJPP11.107]Search in Google Scholar
[9. M. Lovich, C. Creel and K. Hong, Carrier proteins determine local pharmacokinetics and arterial distribution of paclitaxel, J. Pharm. Sci. 90 (2001) 1324-1335; DOI: 10.1002/JPS.1085.10.1002/jps.1085]Search in Google Scholar
[10. R. Braun-Dullaeus, M. Mann and V. Dzau, Cell cycle progression: new therapeutic target for vascular proliferative disease, Circulation 98 (1998) 82-89; DOI: 10.1161/01.CIR.98.1.82.10.1161/01.CIR.98.1.82]Search in Google Scholar
[11. C. Morton Allison, D. Crossman and J. Gunn, The influence of physical stent parameters upon restenosis, Pathol. Biol. 52 (2004) 196-205; DOI: 10.1016/J.PATBIO.2004.03.013.10.1016/j.patbio.2004.03.013]Search in Google Scholar
[12. C. Rogers, Optimal stent design for drug delivery, Rev. Cardiovasc. Med. 5 (2004) S9-S15.]Search in Google Scholar
[13. K. Lau, A. Johan, U. Sigwart and J. Hung, A stent is not just a stent: stent construction and design do matter in its clinical performance, Singapore Med. J. 45 (2004) 305-312.]Search in Google Scholar
[14. A. Colombo, G. Stankovic and J. W. Moses, Selection of coronary stents, J. Am. Coll. Cardiol. 40 (2002) 1021-1033.10.1016/S0735-1097(02)02123-X]Search in Google Scholar
[15. D. Stoeckel, C. Bonsignore and S. Duda, A survey of stent designs, Minim. Invasive Ther. Allied Technol. 11 (2002) 137-147.10.1080/136457002760273340]Search in Google Scholar
[16. L. Lim, Biocompatability of stent materials, MIT Undergrad. Res. J. 11 (2004) 33-37.]Search in Google Scholar
[17. J. Bier, P. Zalesky and S. Li, A new bioabsorbable intravascular stent: in vitro assessment of hemodynamic and morphometric characteristics, J. Interven. Cardiol. 5 (1992) 187-194.]Search in Google Scholar
[18. B. Berk, J. Gordon and R. Alexander, Pharmacologic roles of heparin and glucocorticoids to prevent restenosis after coronary angioplasty, J. Am. Coll. Cardiol. 17 (1991) 111B-117B; DOI: 10.1016/0735-1097(91)90946-7.10.1016/0735-1097(91)90946-7]Search in Google Scholar
[19. C. Pepine, J. Hirshfeld and R. Macdonald, A controlled trial of corticosteroids to prevent restenosis after coronary angioplasty, M-HEART Group Circ. 81 (1990) 1753-1761; DOI: 10.1161/01.CIR.81.6.1753.10.1161/01.CIR.81.6.1753]Search in Google Scholar
[20. I. De Scheerder, K. Wang and K. Wilczek, Local methylprednisolone inhibition of foreign body response to coated intracoronary stents, Coron. Artery. Dis. 7 (1996) 161-166.10.1097/00019501-199602000-00011]Search in Google Scholar
[21. A. M. Lincoff, J. G. Furst and S. G. Ellis, Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model, J. Am. Coll. Cardiol. 29 (1997) 808-816; DOI: 10.1016/S0735-1097(96)00584-0.10.1016/S0735-1097(96)00584-0]Search in Google Scholar
[22. D. Holmes, M. Savage and J. LaBlanche, Results of prevention of restenosis with tranilast and its outcomes (PRESTO) trial, Circulation 106 (2002) 1243-1250. DOI: 10.1161/01.CIR.0000028335.31300DA.]Search in Google Scholar
[23. A. Farb, M. John, E. Acampado, F. D. Kolodgie, M. F. Prescott and R. Virmani, Oral everolimus inhibits in-stent neointimal growth, Circulation 106 (2002) 2379-2384; DOI: 10.1161/01.CIR.0000033973.06059.04.10.1161/01.CIR.0000033973.06059.04]Search in Google Scholar
[24. P. B. Schiff and S. B. Horwitz, Taxol stabilizes microtubules in mouse fibroblast cells, Proc. Natl. Acad. Sci. USA 77 (1980) 1561-1565.10.1073/pnas.77.3.1561]Search in Google Scholar
[25. P. W. Serruys, Long-term effects of angiopeptin treatment in coronary angioplasty: reduction of clinical events but not angiographic restenosis, Circulation 92 (1995) 2759-2760.]Search in Google Scholar
[26. R. K. Aggarwal, D. C. Ireland, M. A. Azrin, M. D. Ezekowitz, D. P. de Bono and A. H. Gershlick, Antithrombotic potential of polymer-coated stents eluting platelet glycoprotein IIb/IIIa receptor antibody, Circulation 94 (1996) 3311-3317; DOI: 10.1161/01.CIR.94.12.3311.10.1161/01.CIR.94.12.3311]Search in Google Scholar
[27. C. Li, W. J. Cantor, N. Nili, R. Robinson, L. Fenkell and Y. L. Tran, Arterial repair after stenting and the effects of GM6001, a matrix metalloproteinase inhibitor, J. Am. Coll. Cardiol. 39 (2002) 1852-1858; DOI: 10.1016/S0735-1097(02)01873-9.10.1016/S0735-1097(02)01873-9]Search in Google Scholar
[28. C. Rogers, S. Parikh, P. Seifert and E. R. Edelman, Endogenous cell seeding. Remnant endothelium after stenting enhances vascular repair, Circulation 94 (1996) 2909-2914; DOI: 10.1161/01.CIR.94.11.2909.10.1161/01.CIR.94.11.29098941120]Search in Google Scholar
[29. J. Aoki, P. W. Serruys, H. van Beusekom, A. T. Ong, E. P. McFadden and G. Sianos, Endothelial progenitor cell capture by stents coated with antibody against CD34: The healing-FIM (healthy endothelial accelerated lining inhibits neointimal growth-first in man) registry, J. Am. Coll. Cardiol. 45 (2005) 1574-1579.]Search in Google Scholar
[30. D. J. Cohen, Economics of coronary restenosis: implications of drug-eluting stents, http://www.tctmd.com/show.aspx?id=58808; last access: April 22, 2012]Search in Google Scholar
[31. P. W. Serruys, P. de Jaegere, F. Kiemeneij, C. Macaya, W. Rutsch, G. Heyndrickx, H. Emanuelsson, J. Marco, V. Legrand, P. Materne, J. Belardi, U. Sigwart, A. Colombo, J. J. Gay, P. Henvel, J. Delcan and M. Morel, A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease, New Engl. J. Med. 331 (1994) 489-495; DOI: 10.10.1056/NEJM199408253310801.10.1056/NEJM199408253310801]Search in Google Scholar
[32. H. Tamai, K. Igaki, E. Kyo, K. Kosuga, A. Kawashima, S. Matsui, H. Komori, T. Tsuji, S. Motohara and H. Uehata, Initial and 6-month results of biodegradable poly-L-lactic acid coronary stents in humans, Circulation 102 (2000) 399-404; DOI: 10.1161/01.CIR.102.4.399.10.1161/01.CIR.102.4.399]Search in Google Scholar
[33. J. A. Ormiston, P. W. Serruys, E. Regar, D. Dudek, L. Thuesen, M. W. Webster, Y. Onuma, H. M. Garcia-Garcia, R. McGreevy and S. Veldhof, A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial, Lancet 371 (2008) 899-907; DOI: 10.1016/S0140-6736(08)60415-8.10.1016/S0140-6736(08)60415-8]Search in Google Scholar
[34. J. A. Ormiston and P. W. Serruys, Bioabsorbable coronary stents, Circ. Cardiovasc. Interv. 2 (2009) 255-260; DOI: 10.1161/CIRCINTERVENTIONS.109.859173.10.1161/CIRCINTERVENTIONS.109.859173]Search in Google Scholar
[35. S. Ramcharitar and P. W. Serruys, Fully biodegradable coronary stents: progress to date, Am. J. Cardiovasc. Drugs 8 (2008) 305-314.10.2165/00129784-200808050-00003]Search in Google Scholar
[36. R. Erbel, C. Di Mario, J. Bartunek, J. Bonnier, B. de Bruyne, F. R. Eberli, P. Erne, M. Haude, B. Heublein, M. Horrigan, C. Ilsley, D. Bose, J. Koolen, T. F. Luscher, N. Weissman and R. Waksman, Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial, Lancet 369 (2007) 1869-1875; DOI: 10.1016/S0140-6736(07)60853-8.10.1016/S0140-6736(07)60853-8]Search in Google Scholar
[37. N. Tada, R. Virmani, G. Grant, L. Bartlett, A. Black, C. Clavijo, U. Christians, R. Betts, D. Savage, S. H. Su, J. Shulze and S. Kar, Polymer-free biolimus a9-coated stent demonstrates more sustained intimal inhibition, improved healing, and reduced inflammation compared with a polymer-coated sirolimus-eluting cypher stent in a porcine model, Circ. Cardiovasc. Interv. 3 (2010) 174-183; DOI: 10.1161/CIRCINTERVENTIONS.109.87522.]Search in Google Scholar
[38. J. R. Costa, Jr., A. Abizaid, R. Costa, F. Feres, L. F. Tanajura, G. Maldonado, R. Staico, D. Siqueira, A. G. Sousa, R. Bonan and J. E. Sousa, 1-Year results of the hydroxyapatite polymer-free sirolimus-eluting stent for the treatment of single de novo coronary lesions: the VESTASYNC I trial, JACC Cardiovasc. Interv. 2 (2009) 422-427; DOI: 10.1016/j.jcin.2009.02.009.10.1016/j.jcin.2009.02.00919463465]Search in Google Scholar
[39. J. Aoki, P. W. Serruys, H. van Beusekom, A. T. L. Ong, E. P. McFadden and G. Sianos, Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) registry, J. Am. Coll. Cardiol. 45 (2005) 1574-1579; DOI: 10.1016/j.jacc.2005.01.048.10.1016/j.jacc.2005.01.04815893169]Search in Google Scholar
[40. H. J. Duckers, S. Silber, R. D. Winter, P. D. Heijer, B. Rensing and M. Rau, Circulating endothelial progenitor cells predict angiographic and intravascular ultrasound outcome following percutaneous coronary interventions in the HEALING-II trial: evaluation of an endothelial progenitor cell capturing stent, EuroIntervention 3 (2007) 67-75.]Search in Google Scholar
[41. M. Co, E. Tay, C. H. Lee, K. K Poh, A. Low and J. Lim, Use of endothelial progenitor cell capture stent (Genous Bio-Engineered R Stent) during primary percutaneous coronary intervention in acute myocardial infarction: Intermediate- to long-term clinical follow-up, Am. Heart. J. 155 (2008) 128-132; DOI: 10.1016/j.ahj.2007.08.031.10.1016/j.ahj.2007.08.03118082503]Search in Google Scholar
[42. A. Abizaid and J. R. Costa, Jr., New drug-eluting stents: An overview on biodegradable and polymer-free next-generation stent system, Circ. Cardiovasc. Interv. 3 (2010) 384-393; DOI: 10.1161/CIRCINTERVENTIONS.109.891192.10.1161/CIRCINTERVENTIONS.109.89119220716758]Search in Google Scholar
[43. C. Lovadahl, J. Thyber and A. Hultgardh-Nilsson, The synthetic metalloproteinase inhibitor batimastat suppresses injury induced phosphorylation of MAP kinase ERK/ERK2 and phenotypic modification of arterial smooth muscle cells in vitro, J. Vasc. Res. 37 (2000) 345-354; DOI: 10.1159/000025750.10.1159/00002575011025397]Search in Google Scholar
[44. P. W. Serruys, S. Garg, A. Abizaid, J. Ormiston, S. Windecker, S. Verheye, C. Dubois, J. Stewart, K. E. Hauptmann, J. Schofer, K. Stangl, B. Witzenbichler, M. Wiemer, E. Barbato, T. de Vries, A. M. den Drijver, H. Otake, L. Meredith, S. Toyloy and P. Fitzgerald, A randomised comparison of novolimus-eluting and zotarolimus eluting coronary stents: 9-month follow-up results of the EXCELLA II study, EuroIntervention 6 (2010) 195-205.]Search in Google Scholar